Key Products
®
Kaishi
GENERIC NAME: Alprostadil Injection
TRADE NAME: Kaishi
【Indications】
1. To treat limb ulcers caused by chronic arterial occlusion (thromboangiitis obliterans, occlusive arteriosclerosis, etc.) and rest pain in the limbs caused by microvascular circulation disorders, and improve microcirculation disturbance of cardio cerebral vessels.
2. To inhibit intravascular thrombosis after transplantation as antithrombotic therapy after organ transplantation.
3. To relieve hypoxemia and maintain catheter blood flow before surgical treatment of arterial catheter-dependent congenital heart disease.
4. Adjuvant therapy of chronic hepatitis.
For healthcare professionals only
®
Kaifen
GENERIC NAME: Flurbiprofen Axetil Injection
TRADE NAME: Kaifen
【Indications】
Postoperative and cancer analgesia.
【Dosage and Administration】
Usually, 50 mg of flurbiprofen axetil is given intravenously each time in adults, as slowly as possible (more than 1 minute), using the analgesic pump as needed, and repeated if necessary. The dose may be incr eased or decreased based on the patient’s age and symptoms. In general, this product should be used when oral drugs cannot be taken or oral drugs are unsatisfactory.
For healthcare professionals only
®
®
Zepusi
GENERIC NAME: Flurbiprofen Cataplasms
TRADE NAME: Zepusi
【Indications】
Analgesia and anti-inflammation for the following diseases and symptoms:
Osteoarthritis, scapulohumeral periarthritis, myotenositis and tenosynovitis, periarthritis of tendon sheath, external humeral epicondylitis (tennis elbow), muscle pain, and swelling and pain caused by trauma.
【Dosage and Administration】
Twice daily, applied to the affected area.
For healthcare professionals only
®
®
Debaian
GENERIC NAME: Flurbiprofen Cataplasms
TRADE NAME: Debaian
【Indications】
Analgesia and anti-inflammation for the following diseases and symptoms:
Osteoarthritis, scapulohumeral periarthritis, myotenositis and tenosynovitis, periarthritis of tendon sheath, external humeral epicondylitis (tennis elbow), muscle pain, and swelling and pain caused by trauma.
【Dosage and Administration】
Twice daily, applied to the affected area.
For healthcare professionals only
®
®
Kaina
GENERIC NAME: Beraprost Sodium Tablets
TRADE NAME: Kaina
【Indications】
To improve ulcers, intermittent claudication, pain, cold sensation and other symptoms caused by chronic arterial occlusive disease.
【Dosage and Administration】
Usually, adults take it orally after meals. 40 μg at a time, three times a day.
For healthcare professionals only
®
®
Deyou
GENERIC NAME: Pronase Granules
TRADE NAME: Deyou
【Indications】
To dissolve and remove gastric mucus during gastroscopy.
【Dosage and Administration】
15 to 30 minutes before gastroscopy, add 20,000 units of Pronase Granules (1 bag) and 1 g of sodium bicarbonate to 50 to 80 ml of drinking water (20-40 ° C), shake to make it dissolved, and take orally.
For healthcare professionals only
®
®
Debaining
GENERIC NAME: Lidocaine Cataplasms
TRADE NAME: Debaining
【Indications】
To relieve postherpetic neuralgia and be only used on intact skin.
【Dosage and Administration】
This product is used on intact skin to cover the most painful area. Apply according to the prescribed amount (at most 3 patches at the same time), and the cumulative application time within 24 hours shall not exceed 12 hours. Patients can cut this product into small pieces with scissors before removing the plastic covering according to the area of the pain site. It is recommended to reduce the application area in frail patients or patients with hepatic and renal insufficiency.
If the patient can't tolerate the irritation or burning sensation during the application, this product can be removed until the irritation subsides and then reused.
When this product is used in combination with preparations containing local anesthetics, the total absorption of all preparations must be considered.
For healthcare professionals only
®
®
Kaiyu
GENERIC NAME: Vildagliptin Tablets
TRADE NAME: Kaiyu
【Indications】
This product is indicated to treat type 2 diabetes mellitus.
- This product can be used as monotherapy when blood glucose cannot be effectively controlled by diet and exercise;
- This product may be combined with metformin when metformin as monotherapy still cannot effectively control blood glucose at its maximum tolerated dose;
- This product may be combined with insulin when insulin cannot effectively control blood glucose at the stable dose;
-This product may be combined with sulphonylureas when sulphonylureas cannot effectively control blood glucose at the stable dose.
For healthcare professionals only
®
®
Research and Innovations
Developed several innovative products with international leading therapeutic concept, filled the domestic unmet clinical needs, and won the second prize of National Science and Technology Progress Award
Achievement
Overview
With excellent innovative drug R&D system and six high-end formulation technology platforms, undertaken several “National and Beijing Science and Technology Major Project” projects.
Technology Platform
Adhere to the innovation driven internationalization strategy, hold several global leading core technologies, develop state-recognized enterprise technology centers, lead the world pharmaceutical innovation.
Collaboration
As a lead company integrated innovative drug development and high-end formulation technologies, Tide would like to collaborate with domestic and oversea companies and institutes to achieve win-win situation with mutual benefit.
News Center
-
Tide Pharmaceutical launches DPP-4 inhibitor oral hypoglycemic agent Vildagliptin Tablet
Vildagliptin Tablet, a new oral hypoglycemic agent developed by Beijing Tide Pharmaceutical Co., Ltd., has obtained drug registration approval notice issued by National Medical Products Administration of the People's Republic of China (approval number: State Drug Approval H20203163). Originally filed as a class 4 new chemical drug, this product is deemed to have passed generic drug quality and efficacy consistency evaluation, it was included on the 2017 National Reimbursement Drug List.
넶144 2020-12-01
CONTACT US
Address: 8 Rongjing East Street, Beijing Economic Technological Development Area, 100176, China
Telephone:010-67880648
Medical consultation and adverse reaction reports
Telephone:010-67870530(weekday8:30-17:00)
E-mail:pv@tidepharm.com
Copyright: Beijing Tide Pharmaceutical Co., Ltd 京ICP备05013257号
京公网安备110301000319号 互联网药品信息服务资格证书编号: (京)-非经营性-2014-0076